Anavex Life Sciences Corporation
Research Anavex Life Sciences Corporation (AVXL) on Bullrun: market cap USD 138.12M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAVXL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 138.12M
- Financial periodQ2 2026
- RevenueUSD 0
- Net incomeUSD 7.82M
- Free cash flow-USD 9.10M
Valuation Snapshot
latest market cap is USD 138.12M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 46.38M | -USD 39.04M | n/a | -0.54 | USD 102.58M | n/a | USD 94.87M |
| FY2024 | USD 0 | -USD 43.00M | -USD 30.81M | n/a | -0.52 | USD 132.19M | n/a | USD 120.26M |
| FY2023 | USD 0 | -USD 47.51M | -USD 27.79M | n/a | -0.6 | USD 151.02M | n/a | USD 141.85M |
| FY2022 | USD 0 | -USD 47.98M | -USD 24.24M | n/a | -0.62 | USD 149.16M | n/a | USD 142.49M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 138.12M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 329.91M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 912.74M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 764.23M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 721.93M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.32B | n/a | n/a | n/a |
About Anavex Life Sciences Corporation
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Anavex Life Sciences Corporation's market cap?
Anavex Life Sciences Corporation's market capitalization is USD 138.12M.
What does Anavex Life Sciences Corporation do?
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer .